Taisho, Ribomic Join To Develop Nucleic Acid-Based Treatments
This article was originally published in PharmAsia News
Taisho Pharmaceutical has teamed with Ribomic, a Japan startup, to develop drugs based on nucleic acid for a wide range of disorders, with clinical trials to begin in four years.
You may also be interested in...
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.